Nissay Asset Management Corp Seagen Inc. Transaction History

Nissay Asset Management Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $287,839 - $324,888	1,503 Added 8.9%	18,389 $3.9 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $109,581 - $120,450	584 Added 3.58%	16,886 $3.25 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $55,884 - $88,949	-438 Reduced 2.62%	16,302 $3.3 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $4,929 - $5,845	-42 Reduced 0.25%	16,740 $2.15 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $85,625 - $114,009	633 Added 3.92%	16,782 $2.3 Million
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $15,233 - $25,106	140 Added 0.87%	16,149 $2.86 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $53,226 - $70,243	445 Added 2.86%	16,009 $2.31 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $48,473 - $64,892	340 Added 2.23%	15,564 $2.41 Million
Q3 2021 Nov 10, 2021	BUY	$142.45 - $169.82 $316,096 - $376,830	2,219 Added 17.06%	15,224 $2.59 Million
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $97,122 - $115,830	719 Added 5.85%	13,005 $2.05 Million
Q1 2021 May 11, 2021	BUY	$137.51 - $190.8 $11,825 - $16,408	86 Added 0.7%	12,286 $1.71 Million
Q4 2020 Feb 08, 2021	BUY	$164.63 - $211.93 $2.01 Million - $2.59 Million	12,200 New	12,200 $2.14 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

Stay updated on Nissay Asset Management Corp with notifications on news.